Meda sells NJ facility to DPT; outsources intra-urethral ED drug
Meda has sold a New Jersey facility dedicated to its intra-urethral erectile dysfunction drug Muse as part of a strategic review of its manufacturing network.
Archives for September 3, 2014
Pharma firms ‘saving billions’ in research – by giving away their tech
Pharma’s biggest players have donated more than $102m ($78m) of technology in a project to transform data sharing in clinical trials and “save the industry billions of dollars.”
Ben venue fallout continues to cause headache for Boehringer Ingelheim
Divested sterile manufacturer Ben Venue has continued to cause trouble for Boehringer Ingelheim with a second recall this year of an injectable drug made at the now defunct site.
More CROs expected to go public, Parexel CFO says
Parexel’s future course may depend on the outlook of competing CROs (contract research organizations), a couple of which could potentially go public in the near future, Ingo Bank, SVP and CFO of Parexel, said Wednesday at the Baird 2014 Healthcare...
Xellia says it planned to invest in Raleigh plant before new tax deal
Xellia has agreed to invest $100m in equipment, retain staff and create 40 full time jobs at the plant it bought in Raleigh, North Carolina in return for business incentives.
PPD acquires RCT Logic’s license to clinical trial design tech
CRO Pharmaceutical Product Development (PPD) announced today that it has acquired for an undisclosed sum RCT Logic’s exclusive license from Massachusetts General Hospital (MGH) for the portfolio of patents related to its sequential parallel comparison...